AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UroGen Pharma Ltd. Director's Dealing 2023

Feb 28, 2023

32312_dirs_2023-02-28_c8bc3890-9869-4482-93c6-9b20df9604d6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-10-21

Reporting Person: Nussbaum Ran (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-21	Ordinary Shares	M	47999	$5.94	Acquired	1485168	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-21	Stock Option (right to buy)	$5.94	M	32723	Disposed	2022-12-27	Ordinary Shares (32723)	Indirect
2022-10-21	Stock Option (right to buy)	$5.94	M	15276	Disposed	2022-12-27	Ordinary Shares (15276)	Indirect

Footnotes

F1: On October 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,481,927 shares of securities beneficially owned following reported transaction instead of 1,485,168 shares.